Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Introduction Intravenous (IV) daratumumab has become a standard in the treatment of MM and AL amyloidosis largely due to its significant clinical benefit. Due to the high risk of infusion-related reactions (IRRs), it is associated with prolonged infusion times. These lengthy administrations can limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, David, Jhaveri, Radhika, Shah, Bhavesh, Blevins, Frances, Rodriguez, Alexamil, Sarosiek, Shayna, Lerner, Adam, Sloan, John Mark, Sanchorawala, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
905.Outcomes Research-Malignant Conditions (Lymphoid Disease)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330229/
http://dx.doi.org/10.1182/blood-2020-135992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330229/
http://dx.doi.org/10.1182/blood-2020-135992

Ejemplares similares